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ABSTRACT 
The present investigation was aimed at preparation and evaluation of mouth dissolving films (MDFs) of an anti-histamine drug, 
Chlorpheniramine Maleate (CPM) to enhance convenience and compliance to the elderly and paediatric patients. The MDFs were prepared using 
wet film applicator and evaluated for physicochemical and physicomechanical properties. MDFs were prepared with 0.6% and 0.8% w/w CPM. 
The MDFs with 0.8% w/w drug load showed re-crystallisation within 10 days, while the MDFs with 0.6% w/w CPM load were transparent with 
no re-crystallization. The effect of film formers, film thickness, film modifiers, saliva stimulating and soothing agents on the physicomechanical 
properties and CPM release from MDFs were evaluated. MDFs casted at 30mil thickness containing poly ethylene glycol (PEG-400) as plasticizer 
showed superior CPM release rates along with good physicomechanical properties. MDFs with hydroxy propyl methyl cellulose (HPMC) E3 as 
film former gave superior CPM release rate when compared to E5 and E15 formulations. MDFs with poly vinyl pyrrolidone K30 (PVPK30) gave 
superior drug release properties when compared to MDFs without PVP K30. The MDFs with citric acid (CA) and xylitol gave superior CPM 
release than the other MDFs. Release kinetics data reveals diffusion as drug release mechanism. 
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INTRODUCTION 
As a site for drug delivery, oral cavity (intraoral route) offers 
advantages over the conventional gastro-intestinal route, the 
parenteral and other mucosal routes of drug administration. 
It provides direct entry into the systemic circulation thereby 
avoiding the hepatic first pass effect with ease of 
administration and the ability to terminate drug delivery 
when required 1. Recent developments in the technology 
have presented viable dosage alternatives from oral route 
for paediatrics, geriatric, bedridden, nauseous or 
noncompliant patients 2. Buccal drug delivery has lately 
become an important route of drug administration. Various 
bio adhesive mucosal dosage forms have been developed, 
which includes adhesive tablets, gels, ointments, patches and 
more recently the use of polymeric films for buccal delivery, 
also known as mouth dissolving films 3. Mouth dissolving 
films (MDFs), a new and novel drug delivery system for per 
oral delivery of the drugs, were developed based on the 
technology of the transferral patch. MDFs have gained 
popularity due to its availability in various sizes and shapes. 
The film is placed on the top or the floor of the tongue 4. 
When put on the tongue, this film disintegrates 
instantaneously, releasing the drug which dissolves in the 
saliva. Some drugs are absorbed from the mouth, pharynx, 
and oesophagus as the saliva passes down into the stomach. 
In such cases, the bioavailability of the drug is significantly 
greater than that observed for conventional tablets 5. 
Chlorpheniramine Maleate (CPM) is a histamine H1 
antagonist and indicated for the treatment of hay fever, 
common cold, rhinitis, urticaria, allergic reactions, and 
asthma 6. CPM is used in the treatment of allergy act by 
competing with histamine for H1-receptor sites on effector 
cells. They thereby prevent, but do not reverse, responses 
mediated by histamine alone. CPM undergoes first pass 
metabolism and has an oral bioavailability of 25-50% 7. It is 
available in syrup, tablet, sprays and lozenge forms and is 
available in the market as over-the-counter drugs named 
Cadistin, Cepiam TR, Chloram, Cipium, etc. Keeping in view 
the patient compliance and the need for better therapeutic 
efficacy the present investigation was aimed at the 
preparation and evaluation of CPM MDFs and to ensure 
quick onset of action. 
Few reports were published on the formulation and 
evaluation of CPM MDFs and none of them were developed 
and evaluated systematically. In most of the works reported 
so far, MDFs were prepared in petri plates, moulds, etc. and 
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the films were dried at 40-45°C overnight and this procedure 
may not result in uniformity in thickness and drug content 
and thereby vary the drug release rates 8-10. Moreover, no 
works on the influence formulation variables like film 
thickness, polymer viscosities, surfactants and saliva 
stimulating agents were reported. MDFs were not evaluated 
thoroughly for the drug loading effect on the crystallization 
and characterization studies. Hence, the present 
investigation was aimed to prepare CPM MDFs using wet 
film applicator, an industrially scalable technique and 
evaluate them systematically keeping in view all the above 
parameters. 
MATERIALS AND METHODS 
Materials 
CPM was obtained from Aurobindo India Ltd., Hyderabad. 
HMPC E3, E5, E15 were obtained from Colorcon Asia Ltd., 
India. Ethanol, PVP K30 and SLS were purchased from Loba 
Chemie, Mumbai. Xylitol was purchased from Roquette 
laboratories, France. Pine apple flavour was obtained from 
Darwin laboratories, Vijayawada. All the ingredients of 
analytical grade were used.  
Preparation of Artificial Saliva 
Artificial saliva was prepared by dissolving sodium chloride-
0.844g; potassium chloride-1.2g; calcium chloride dihydrate-
0.193g; magnesium chloride hexahydrate-0.111g and 
potassium phosphate dibasic-0.342g were added one by one 
to 500mL of distilled water and then the volume was made 
up to 1000 mL using the distilled water. The pH was adjusted 
with 0.1N HCl to 5.711. 
Preparation of CPM MDFs 
CPM MDFs were prepared as per formulae given in Table 1 
to a batch size of 5g. Drug was dissolved in a mixture of 
solvents (water and ethanol) in a beaker and other 
ingredients were added one by one and finally polymer 
hydroxy propyl methyl cellulose (HPMC) was added and 
mixed thoroughly. The mixture was sonicated for 5 minutes 
to remove entrapped air bubbles and casted on a glass plate 
with a wet film applicator set at 30 mil (750µm) and 40 mil 
(1000µm) and it was dried at 45°C for 60min in hot air oven. 
Then the dried films were peeled off from the glass plate, cut 
into appropriate sizes, and stored in desiccators until use.  
HPLC analysis of CPM 
Chromatographic Conditions 
An HPLC System (Shimadzu) comprising of a Degasser (DGU-
20A3), Binary pump (LC- 20 AD), an Auto-sampler (SIL- 20 
AC HT) and a PDA-detector (SPD M20A) was used to develop 
method for analysis of CPM in samples. LC solution software 
was used to collect and process the data. Mobile phase 
consisting of 0.02% Formic acid: Methanol (68:32 v/v) at 
used at a flow rate of 1mL/min.  For quantitative analytical 
purpose 10μL of the samples were injected and the eluents 
were monitored at 220nm and the separation was achieved 
at an ambient temperature. Under these LC conditions the 
CPM was eluted at 4.8 min. 
Fourier transform infrared spectroscopic Analysis 
(FTIR): 
Samples were analysed using an ATR-FTIR spectrometer 
(Bruker, Germany) and the powder or film sample was 
simply placed onto the ATR crystal and the sample spectrum 
was collected. ATR spectra were measured over the wave 
number range of 4000-500 cm-1at a resolution of 1.0 cm-1.  
 
Evaluation Parameters for CPM MDFs 
Morphological Properties 
The films were packed in aluminium foil pouches and were 
stored at room temperature (25 ± 3°C) with relative 
humidity of approximately 65 ± 5% and were tested 
periodically every month for a period of 6 months. 
Properties such as homogeneity, colour, transparency, and 
surface of CPM MDFs were tested visually. 
Thickness 
The thickness of film was evaluated using a screw gauge with 
a range of 0-10mm and revolution 0.001 mm. Anvil of the 
thickness gauge was turned and the film was inserted after 
making sure that the pointer was set to zero 15-17. The film 
was held on the anvil and the reading on the dial was noted 
down. The estimations were carried out in triplicate. 
Drug Content 
One cm2 film was taken in a 10mL volumetric flask and 
dissolved in 5mL of artificial saliva and then final volume 
was made up with artificial saliva. Samples were suitably 
diluted with artificial saliva and were analysed. The 
estimations were carried out in triplicate. 
Variation of Mass 
Mass of one cm2 film from different batches of the 
formulations was noted and the estimations were carried out 
in triplicate. 
In Vitro Disintegration Studies  
 In MDFs the disintegration and dissolution procedures are 
hardly distinguishable. If the MDF disintegrates it 
concurrently dissolves in a small amount of saliva which 
makes it difficult to mimic these natural conditions and 
measures with an adequate method. In the present 
investigation two methods of disintegration were adopted to 
mimic natural conditions.  
Drop Method  
In this method, the films were placed on a glass slide and 
placed planar on a petri dish. One drop of distilled water was 
dropped by a pipette onto the oral films 15-17. The time until 
the film dissolves and forms a hole in the film was measured. 
The estimations were carried out in triplicate. 
Petri dish Method  
In this method 2mL of distilled water was placed in a petri 
dish and a film of 2x2 cm2 was placed on the surface of the 
water and the time required to dissolve the film completely 
was measured. The estimations were carried out in 
triplicate. 
Tensile Strength 
Tensile strength is the maximum stress applied to a point at 
which the film specimen breaks 
[12]. It is calculated by the load at rupture divided by the 
cross-sectional area of the film as given below: 
Tensile strength =
                    
                          
 
Tensile strength of MDFs was measured using Mini Tech 
Tensiometer-UTM9051 (Dak Systems Inc., Mumbai, India) 
fitted with a load cell of 500N (50kg) capacity and the data 
was collected using Test Bench II software 15-17. Samples of 
appropriate film thickness with fixed dimensions (LxW-
10*2cm) were fixed between pneumatic grips with a gauge 
dimension of 3cm length between grips. All the dimensions 
were entered into software to calculate the cross-sectional 
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area.  The film was carefully placed in between the 
pneumatic grips without any loose folds. Instrument was 
operated at speed of 5mm/min until the film breaks. Percent 
elongation data was also computed from the software for 
each sample. Whole experiment was carried out in triplicate. 
Percent Elongation  
When stress is applied the film sample stretches and is 
referred to as strain. Strain is basically the deformation of 
the film divided by the original dimension of the film. 
Generally, elongation of the film increases as the plasticizer 
concentration increases 13.  Percentage elongation was 
calculated by measuring the increase in length of the film 
after tensile strength measurement by using the following 
formula. 
Percent Elongation =
            
  
 
Where, L = Final length, L0 = initial length. 
Percent elongation was computed from the Test bench II 
software for tensile strength measurement. The estimations 
were carried out in triplicate. 
Folding Endurance 
Folding endurance is determined by repeated folding of the 
film at the same place till the film breaks.  This gives an 
indication of brittleness of the film. The number of times the 
film is folded without breaking is computed as the folding 
endurance value 14.  The estimations were carried out in 
triplicate. 
In Vitro Drug Release Studies 
The in vitro drug release studies were conducted using 
500mL of artificial saliva as dissolution medium with 
modified USP Type V Dissolution Rate Testing Apparatus. A 
temperature of 37°C and 50 rpm were maintained. Each film 
of appropriate size (3.4x 3.4cm2) equivalent to 4mg dose was 
cut and placed on a watch glass covered with nylon wire 
mesh. The watch glass was then dropped into dissolution 
flask. 2mL samples were withdrawn at predetermined time 
intervals 2, 5, 10, 20, 30, 40, 50, 60, 80, 100, 120, 180, 240, 
300sec and every time replaced with 2mL of fresh 
dissolution medium. The samples were analysed using HPLC 
method. The drug release experiments were conducted in 
triplicate.  
Stability Studies  
Stability studies were carried out on F9 containing 0.6% 
w/w of CPM and HPMC E3. The MDFs were packed in 
aluminium pouches, sealed and stored at 40°C /75 ± 5% RH 
for 6 months. The appearance, weight and drug content 
properties of the MDFs were examined. 
Statistical Analysis 
Results of experimental data were subjected to one-way 
ANOVA (using Fisher’s LSD Post HOC test) using SYSTAT 
software (SYSTAT Software Inc., San Jose, USA). Results with 
‘p’ value of less than 0.05 were considered as of significant 
variance. 
RESULTS AND DISCUSSION 
Preparation and Physical Characterization of CPM MDFs 
In the present investigation the MDFs were prepared using a 
wet film applicator of the ease of removal and quick drying 
of the films, which is also a commercially scalable technique. 
Initially placebo MDFS were prepared using different 
polymers like HPMC E3, HPMC E5, HPMC E15, methyl 
cellulose and sodium carboxy methyl cellulose (NaCMC), 
using PEG-400 as plasticizer. The MDFs were observed for 
their film forming capacity and their appearance. Finally, 
from the trails made and results obtained, HPMC E3, HPMC 
E5 and HPMC E15 were selected for further development. 
Initially MDFs were prepared with CPM load of 0.8% using 
water-ethanol as solvents, and the films were casted at 30 
mil thickness. However, crystallization was observed within 
a period of 10 days. Hence further trials were made with 
CPM load of 0.6 % and the films were casted at 30 mil and 40 
mil thickness. The MDFs were transparent with no 
crystallization and all the formulae were given in Table 1.A 
5g batch size of formulations were given approximately 
88.16 cm2 film area. 
 
Table 1: Composition of different CPM MDFs 
Ingredients (mg) 
Formulae (5g batch size) 
F1 F2 F2A* F3 F4 F5 F6 F7 F8 F9 F10 
CPM 40 30 30 30 30 30 30 30 30 30 30 
HPMC E3 375 375 375 - - 375 375 - - 375 - 
HPMC E5 - - - 375 - - - 375 375 - 375 
HPMC E15 - - - - 375 - - - - - - 
PVP K30 - - - - - 2 - 2 - 2 2 
SLS - - - - - - 2 - 2 - - 
PEG 400* 25 25 25 25 25 25 25 25 25 25 25 
Water* 1785 1785 1785 1785 1785 1785 1785 1785 1785 1785 1785 
Ethanol* 2730 2740 2740 2740 2740 2738 2738 2738 2738 2725.5 2725.5 
Citric acid - - - - - - - - - 12.5 12.5 
Colouring agent 10 10 10 10 10 10 10 10 10 10 10 
Flavouring agent 10 10 10 10 10 10 10 10 10 10 10 
Xylitol 25 25 25 25 25 25 25 25 25 25 25 
*All the amounts were taken based up on their density. 
FTIR Analysis 
The CPM showed characteristic peaks at 1577.78cm-
1(aromatic amine bending), 2967.11cm-1 (C-H bending), 
1739.17cm-1(C=O stretching), 1621.30cm-1(C=C stretching), 
1351.33 cm-1(C-N stretching), 756.15 cm-1 (C-Cl bending). 
These characteristic peaks of CPM were all retained in the 
MDFs. These characteristic peaks of CPM were all retained in 
the MDFs. These results indicate that there is no interaction 
between CPM and excipients in MDFs. The FT-IR spectrums 
of CPM were shown in Fig 1. 
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Figure 1: FTIR Sectra for pure CPM(--), F9 (--) and F10 (--) 
 
Morphological properties 
CPM MDFs were visually tested for homogeneity, 
transparency, colour and smoothness. MDFs formulated with 
0.8% w/w CPM were transparent initially but turned opaque 
within 10 days and is due to crystallization of CPM.MDFs 
with 0.6% CPM showed no change in properties even at the 
end of 6month time period and no crystallization of CPM was 
observed. The photographs were shown in Fig.2. The 
morphological characterization of MDFs was further 
established by visualizing MDFs under binocular microscope 
(Olympus-CH20i) with magnification 10x.  
 
 
Figure 2: Photographs of CPM MDFs 
 
Thickness 
The thickness was measured with screw gauge at different 
places of MDFs in order to evaluate the reproducibility of 
preparation method. Around 90% of wet film thickness was 
lost during drying. The results were given in Table 2 and a 
good uniformity of thickness was observed. MDFs casted at 
40 mil thickness and MDFs with PVP and SLS showed higher 
thickness values compared to other formulations. 
 
Table 2: Physico-mechanical properties of different CPM MDFs 
Formulations 
Drug content 
(mg/cm2) 
(n=3) 
 
Mass variation 
(mg) 
(n=3) 
 
Thickness (µm) 
(n=6) 
 
Disintegration time(sec) 
Drop method 
(n=3) 
Petri dish 
method 
(n=3) 
F2 0.39 ± 0.01 2.60 ± 0.26 73.33 ± 5.16 12.33 ± 0.57 22.33 ± 1.58 
F2A 0.41 ± 0.02 2.73 ± 0.05 83.33 ± 5.16 17.33 ± 0.57 27.00 ± 1.58 
F3 0.39 ± 0.02 2.53 ± 0.05 78.33 ± 4.08 14.66 ± 0.57 23.66 ± 1.15 
F4 0.37 ± 0.01 2.86 ± 0.05 93.33 ± 5.16 16.00 ± 0.00 24.66 ± 0.58 
F5 0.39 ± 0.03 2.80 ± 0.10 78.33 ± 4.08 11.00 ± 1.00 19.66 ± 1.15 
F6 0.38 ± 0.02 2.63 ± 0.23 76.66 ± 5.16 11.33 ± 1.15 21.33 ± 1.73 
F7 0.39 ± 0.02 2.73 ± 0.05 85.00 ± 5.47 13.33 ± 0.57 20.33 ± 0.58 
F8 0.38 ± 0.03 2.63 ± 0.15 85.33 ± 5.16 14.33 ± 0.57 21.33 ± 0.57 
F9 0.40 ± 0.02 2.96 ± 0.05 81.66 ± 4.08 10.33 ± 0.57 18.33 ± 1.58 
F10 0.40 ± 0.02 2.93 ± 0.15 86.66 ± 5.16 12.33 ± 0.57 19.33 ± 0.58 
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Drug content 
Films of 1 cm2 were cut from different places (n=3) of whole 
film and CPM content was estimated. The results were given 
in Table 2. The results indicated a good uniformity of CPM 
within the film, overall good solubilisation of CPM in MDFs 
was observed. MDFs casted at 40mil thickness gave higher 
CPM content values compared to MDFs casted at 30mil 
thickness which may be due to decrease in film area 
obtained with 30mil thickness. 
Variation of mass 
Films of 1 cm2were cut from different batches and weighed. 
The results are given in Table 2. Same mass of film was 
obtained with three batches of films indicating 
reproducibility of preparation method and formulation. 
In Vitro Disintegration Studies 
The results of disintegration time are given in Table 2. The 
results indicated that HPMC E3 formulations disintegrated 
faster than the E5, E15 which is due to low viscosity of E3 
polymer compared to E5 and E15. The CPM MDFs casted at 
30mil showed faster disintegration rates compared to those 
casted at 40mil. The MDFs with PVP K30 disintegrated faster 
than the MDFs without PVP K30. The MDFs with CA and 
xylitol showed faster disintegration compared to the other 
formulations. The images of MDF (F9) disintegration by drop 
and petridish methods are shown in Fig. 4. 
 
A) 
 
B) 
 
Figure 4: In vitro disintegration of CPM MDFs by A) Drop method B) Petri dish method 
 
Tensile Strength and % Elongation 
MDFs should possess moderate tensile strength and % 
elongation. The results revealed that all films showed 
moderate tensile strength values. With the increase in the 
viscosity of the polymer the tensile strength of the MDF has 
increased. The results were given in Table 3 and shown in 
Fig 5. 
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Figure 5: Comparative Tensile Strength Profiles of CPM MDFs 
 
Table 3: Physico-mechanical properties of different CPM 
MDFs 
Formulations %Elongation Folding endurance 
F2 4.50 ± 0.16 97 
F2A 4.89 ± 0.05 88 
F3 4.66 ± 0.05 94 
F4 5.70 ± 0.26 90 
F5 5.23 ± 0.11 105 
F6 5.25 ± 0.25 102 
F7 4.80 ± 0.16 101 
F8 5.23 ± 0.20 99 
F9 5.24 ± 0.11 117 
F10 5.33 ± 0.11 113 
 
Folding Endurance 
The MDFs prepared with HPMC polymer showed good 
folding endurance. MDFs casted at 40 mil thickness showed 
low folding endurance values compared to other 
formulations. The results were given in Table 3. 
In Vitro Drug Release Studies 
In the present investigation, drug release of MDFs was 
carried out using USP Type-V dissolution rate testing 
apparatus. 500mL of artificial saliva was used as dissolution 
medium in order to mimic the in vivo conditions. The in vitro 
drug release profiles of CPM MDFs are shown in Fig. 6. 
Initially to study the effect of film thickness on the release 
rates of CPM from MDFs, formulations were prepared using 
HPMC E3 as film forming agent, PEG-400 as plasticizer and 
films were casted at 30 mil and 40 mil thickness. 30mg of 
CPM (0.6% w/w drug load) was added in each formulation. 
The cumulative percent of CPM released at the end of 5 secs 
is 41.89± 5.89 and 45.76 ± 4.77 for F2 and F2A respectively. 
Complete CPM release was obtained at 40s and 60s for F2 
and F2A respectively. 
From the results obtained, it was found that the formulations 
casted at 30 mil thickness (F2) gave superior results 
compared to formulations casted at 40 mil thickness (F2A). 
An increase in thickness of the MDFs (as in case of 40 mil 
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thickness) has resulted in delayed disintegration of films 
which in turn has delayed the drug release from the MDFs. 
This indicates that the release of drug from MDFs is affected 
by the film thickness. Hence the MDFs with 30 mil thickness 
have been selected for the further investigation. 
The studies were continued to evaluate the effect of polymer 
viscosities on the rate of CPM release from the MDFs. 
Formulations (F2, F3 and F4) were casted at 30 mil thickness 
and using PEG-400 as plasticizer and HPMC E3, E5 and E15 
as film formers. 30mg of CPM (0.6% drug load) was added to 
each formulation. The cumulative percent of CPM released at 
the end of 5sec is 41.89 ± 5.88, 34.62 ± 7.73 and 24.88 ± 5.27 
for formulation F2, F3 and F4 respectively. The complete 
release of CPM was obtained at 40sec, 50sec and 60sec 
respectively. The release rate of F2 is significantly higher 
than the F3 and F4 formulations. This can be due to the 
lower viscosity of the HPMC E3 polymer. With an increase in 
the viscosity of the polymer the release of the CPM from MDF 
has decreased significantly. Overall, the order of percent of 
CPM released from the MDFs is F2 > F3 > F4. 
The formulations containing HPMC E3 and E5 were selected 
to study the effect of solubilising and/or wetting agents on 
the release of CPM. PVP K30 and SLS were added to the 
formulations at a level of 0.04% (2mg). Cumulative percent 
of CPM released at the end of 5sec is 51.51 ± 3.36 and 47.44 
± 0.85 for formulation F5 (E3 with PVP K30) and F6 (E3 with 
SLS) respectively, while 50.57 ± 3.13 %and 49.6 ± 1.51 % of 
CPM release was observed for formulation F7 (E5 with PVP 
K30) and F8 (E5 with SLS) respectively. The complete 
release of CPM was obtained at 30sec, 40sec, 50sec and 
50sec for F5, F6, F7 and F8 formulations respectively. 
The MDFs with PVP K30 and SLS showed significantly 
superior drug release profiles when compared to the MDFs 
without PVP K30 and SLS. The MDFs with PVP K30 showed 
superior drug release profiles when compared to the films 
with and without SLS. The MDFs with HPMC E3 as film 
forming agent and PVP K30 showed superior results when 
compared to the MDFs with HPMC E5 and PVP K30. Overall 
the MDFs with PVP K30 showed superior drug release 
profiles when compared to the other formulations. 
The effect of saliva stimulating agents and soothing agents 
on the release rates of CPM from the MDFs was also studied. 
CA and xylitol were added to the formulations at 0.25% and 
0.5% levels respectively. Cumulative percent CPM release 
from the MDFs at the end of 5sec was 76.38 ± 2.63 for 
formulation F9 containing HPMC E3 with PVP K30, CA and 
xylitol; and 70.12 ± 1.24 for F10 formulation containing 
HPMC E5 with PVP K30, CA and xylitol. The complete release 
of CPM from the MDFs was obtained at 20sec and 40sec for 
F9 and F10 formulations respectively. The MDF formulations 
with CA and xylitol showed superior CPM release when 
compared to the other formulations. The formulation F9 was 
optimized because of its CPM release profile, 
physicomechanical, physicochemical, in vitro disintegration 
and in vitro drug release properties when compared to the 
other formulations. 
 
 
 
Figure 6: Effect of (A) Thickness (B)Polymer viscosity (C)Solubilizing and Saliva stimulating agents on in vitro CPM 
release from MDFs 
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Drug release kinetics  
To understand the release profiles obtained with CPM MDF 
formulations, the drug release data obtained at different time 
points was fitted into kinetic models such as First Order [18], 
Higuchi model [19]. The first order release rate constant ‘k’ 
(sec-1) values and Correlation Coefficient (R2) values 
calculated from drug release data (0-300 sec) for CPM MDFs.  
When compared to F2, a 1.15 and 1.9 fold decrease was 
observed with F3 and F4 formulations respectively. When 
compared to F2, the ‘k’ values were higher for F5 & F6 
containing PVP K30 & SLS. A 2.18 fold and 1.17fold increase 
was observed for F5 & F6 formulations respectively when 
compared to F2 formulation. When compared to F3, the ‘k’ 
values were higher for F7& F8 containing PVP K30 & SLS. A 
2.35 fold and 1.89 fold increase was observed for F7 & F8 
formulations respectively when compared to F4 formulation.  
A 1.04 fold increase in ‘k’ values was obtained for 
formulation F9 (E3, PVP K30 & CA) when compared to F5 
(E3 and PVP K30); while a 3.27 fold increase in ‘k’ values was 
obtained for formulation F10 (E5, PVP K30 & CA) when 
compared to F7 (E5 and PVP K30). A 1.65 fold increase was 
observed for F9 formulation containing E3 with PVP K30 and 
CA when compared to F10 (E5 with PVP K30 & CA). 
Overall, MDFs with CA and PVP K30 gave higher ‘k’ values 
when compared to MDFs without CA and PVP K30. MDFs 
with PVP and SLS gave higher ‘k’ values compared to MDFs 
without PVP and SLS. MDFs with PVP gave higher ‘k’ values 
than SLS. The Higuchi square root model of all MDFs showed 
good correlation coefficient values (0.814-0.976) indicating 
diffusion as release mechanism.  
Stability Studies: 
Stability studies were carried out for F9 formulation 
containing 0.6% w/w CPM with HPMC E3.  MDFs were 
stored at 40°C with relative humidity of approximately 75 ± 
5% for 6 months. The appearance, weight variation and drug 
content of the MDFs were examined. The appearance of 
MDFs remained unchanged throughout the studies and no 
crystallization was observed. There is no statistically 
significant change observed in weight of MDFs. F9 showed 
96-103% of CPM content after 6 months, indicating that the 
CPM was stable in MDFs. 
CONCLUSIONS 
From this investigation, it can be concluded that CPM can be 
successfully formulated into MDFs. The film properties and 
drug release rates can be affected by the formulation 
variables such as film thickness and polymer viscosities and 
percent drug loading. The casting films with wet film 
applicator resulted in CPM MDFs with reproducible physico-
mechanical and physicochemical properties form batch to 
batch. MDFs casted with 30mil thickness containing PEG-400 
showed good physico-mechanical properties along with 
superior CPM release rates compared to other formulations. 
Formulation F9 was subjected to stability studies and no 
change in appearance, weight and drug content was 
observed indicating that the CPM was stable in the 
formulations. Formulation F9 (0.6% w/w CPM, 7.5 % w/w 
HPMC E3, 0.5 % w/w PEG-400, 0.04 % w/w PVP K30, 0.25% 
CA and 0.5% xylitol) showed better physico-mechanical and 
drug release properties when compared to remaining 
formulations. The administration of CPM as MDFs may 
provide quick onset of action with enhanced oral 
bioavailability and therapeutic efficacy compared to current 
marketed formulations like IR and ODT’s. 
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